Thermo Fisher Scientific has announced a strategic research and development partnership with AstraZeneca BioVentureHub in Gothenburg, Sweden, marking a significant collaboration between two global life science leaders. The partnership will see a dedicated team from Thermo Fisher's PPD clinical research business co-locate with AstraZeneca scientists to drive collaborative innovation in key scientific areas.
Partnership Focus Areas
The collaboration will initially concentrate on three critical technology areas: chromatography, molecular genomics, and proteomics. This focused approach aims to leverage the combined expertise of both organizations to advance pharmaceutical development capabilities and strengthen the broader life science ecosystem.
"This is a unique opportunity to co-locate with AstraZeneca scientists, driving collaborative innovation, strengthening the science ecosystem and driving value generation for all collaborators, giving easy access to cutting edge technologies for emerging life sciences and biotech companies as well as academic groups," said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific.
Strategic Location and Infrastructure
The partnership is strategically positioned within Gothenburg's expanding innovation ecosystem, which includes the GoCo Health Innovation City. This location will also house Thermo Fisher's new bioanalytical laboratory, currently under construction and scheduled to begin operations in March 2026.
The state-of-the-art facility is designed to serve pharmaceutical and biotech customers across Europe and globally, providing leading-edge bioanalytical laboratory capabilities to support all phases of pharmaceutical development. The laboratory represents a significant investment in helping customers deliver life-changing medicines to patients worldwide.
Magnus Björsne, CEO of AstraZeneca BioVentureHub, emphasized the significance of the collaboration: "When two global life science leaders join forces in an open innovation environment, truly exceptional conditions for breakthrough discovery and progress are created. Welcoming Thermo Fisher Scientific into BioVentureHub at AstraZeneca's strategic R&D campus in Gothenburg marks a significant step and unlocks dynamic opportunities for open scientific co-creation."
Global Laboratory Network
The new Swedish facility will complement Thermo Fisher's existing global network of GMP (good manufacturing practices), central, bioanalytical and vaccine science laboratories. Current operations span multiple continents with facilities in Middleton, Wisconsin; Highland Heights, Kentucky; Richmond, Virginia; Athlone, Ireland; Brussels, Belgium; Singapore; and Suzhou, China.
Open Innovation Platform
The AstraZeneca BioVentureHub operates as a unique open innovation platform, providing access to AstraZeneca's scientific expertise, world-class infrastructure, and facilities. Integrated within AstraZeneca's strategic R&D site in Gothenburg, the BioVentureHub enables emerging life science companies and academia to work within focus areas including Pharma, DeepTech, Digital & SustainTech.
The platform promotes innovation by connecting and nurturing collaborations that drive growth for all participants. Notably, all BioVentureHub companies operate independently, with AstraZeneca holding no ownership or innovation rights, maintaining the integrity of the open innovation model.
This partnership represents Thermo Fisher Scientific's continued commitment to its mission of enabling customers to make the world healthier, cleaner and safer, while supporting the development of breakthrough therapies through collaborative scientific innovation.
